Activities per year
Abstract
Objectives
Laboratory confirmed IPD cases are passively notified to the Centre for Disease Prevention and Control of Latvia (CDPC) by laboratories and clinicians.
Materials and Methods
We calculated incidence by age, sex, case fatality, and trend in serotypes by conducting a retrospective population-based study based on national IPD surveillance data.
Results
From 2017 to 2021 371 cases of IPD were reported, including 17 (4,6%) cases reported in age 0-17. The total mean IPD cases during five years are 74,2 cases per year (3,9/100,000). The highest notified incidence was in 2018 at 4.3/100,000, which fell to 3.5 in 2020. The highest mean annual IPD incidence was in infants (7.2) and in the elderly (8.0).
95% (351/371) of all S.pneumoniaein IPD cases were serotyped. PCV10 vaccine serotypes has a decreasing trend from 27% in 2017 to 17,4% in 2021. PCV13 vaccine serotypes had
an increasing trend and rose from 16,2% in 2017 to 36% in 2021 aspatially in children (aged 0-17) and elderly (aged >=65). The most common serotypes among all patients are 19A (13%, 46/351), 3 (12,8%, 45/351) and 8 (11,4%, 40/351) Total case fatality rate in study period was 16,2% (57/371) with the highest in elderly (aged >=65) 16,7% (26/155). The highest case fatality 21,4% was in 2021. 21% (12/57) of all S. pneumoniae death from IPD was associated with serotype 19A.
Conclusions
Surveillance data indicate the importance to change the vaccine in the schedule from
PCV10 to other including more S.pneumoniae serotypes.
Laboratory confirmed IPD cases are passively notified to the Centre for Disease Prevention and Control of Latvia (CDPC) by laboratories and clinicians.
Materials and Methods
We calculated incidence by age, sex, case fatality, and trend in serotypes by conducting a retrospective population-based study based on national IPD surveillance data.
Results
From 2017 to 2021 371 cases of IPD were reported, including 17 (4,6%) cases reported in age 0-17. The total mean IPD cases during five years are 74,2 cases per year (3,9/100,000). The highest notified incidence was in 2018 at 4.3/100,000, which fell to 3.5 in 2020. The highest mean annual IPD incidence was in infants (7.2) and in the elderly (8.0).
95% (351/371) of all S.pneumoniaein IPD cases were serotyped. PCV10 vaccine serotypes has a decreasing trend from 27% in 2017 to 17,4% in 2021. PCV13 vaccine serotypes had
an increasing trend and rose from 16,2% in 2017 to 36% in 2021 aspatially in children (aged 0-17) and elderly (aged >=65). The most common serotypes among all patients are 19A (13%, 46/351), 3 (12,8%, 45/351) and 8 (11,4%, 40/351) Total case fatality rate in study period was 16,2% (57/371) with the highest in elderly (aged >=65) 16,7% (26/155). The highest case fatality 21,4% was in 2021. 21% (12/57) of all S. pneumoniae death from IPD was associated with serotype 19A.
Conclusions
Surveillance data indicate the importance to change the vaccine in the schedule from
PCV10 to other including more S.pneumoniae serotypes.
Original language | English |
---|---|
Pages (from-to) | 380 |
Number of pages | 1 |
Journal | Medicina (Kaunas) |
Volume | 59 |
Issue number | Suppl. 2 |
Publication status | Published - 2023 |
Event | RSU Research Week 2023: Research Week 2023 Rīga Stradiņš University - Riga Stradins University, Riga, Latvia Duration: 27 Mar 2023 → 31 Mar 2023 https://rw2023.rsu.lv/general-information https://rw2023.rsu.lv |
Keywords*
- Pneumococcal
- IPD
- Streptococcus pneumoniae
- Pneumonia
Field of Science*
- 3.3 Health sciences
Publication Type*
- 3.4. Other publications in conference proceedings (including local)
Fingerprint
Dive into the research topics of 'Invasive pneumococcal disease epidemiology in Latvia, 2017-2021'. Together they form a unique fingerprint.Activities
- 1 Oral presentation
-
Epidemiology of Invasive Pneumococcal Disease in Latvia in 2017-2021
Savrasova, L. (Speaker), Zeltiņa, I. (Co-author), Villeruša, A. (Co-author), Krūmiņa, A. (Co-author), Čupeca, H. (Co-author), Brenča, R. (Co-author) & Grope, I. (Co-author)
30 Mar 2023Activity: Talk or presentation types › Oral presentation